Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Plos Neglected Tropical Diseases|April 1, 2021
Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphavirusesJohn M Powers, Nicole N Haese, Michael Denton, et al.
Vaccines|September 28, 2024
Nonreciprocity in CHIKV and MAYV Vaccine-Elicited ProtectionWhitney C Weber, Takeshi F Andoh, Craig N Kreklywich, et al.
Plos Neglected Tropical Diseases|March 13, 2023
Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoproteinJohn M Powers, Zoe L Lyski, Whitney C Weber, et al.
Frontiers in Virology (Lausanne, Switzerland)|February 27, 2025
Differential Type 1 IFN Gene Expression in CD14+ Placenta Cells Elicited by Zika Virus Infection During PregnancyNicole N Haese, Hannah Smith, Kosiso Onwuzu, et al.
Journal of Virology|July 27, 2026
The human cytomegalovirus chemokine binding protein UL22A is necessary for efficient reactivation from latency in CD34+ hematopoietic progenitor cells and humanized miceRebekah L Turner, Nicole L Diggins, Luke Slind, et al.
Plos Neglected Tropical Diseases|March 17, 2025
Development of a virulent O'nyong'nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccineWhitney C Weber, Zachary J Streblow, Takeshi F Andoh, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
The human cytomegalovirus chemokine binding protein UL22A is necessary for efficient reactivation from latency in CD34 + hematopoietic progenitor cells and humanized miceRebekah L Turner, Nicole L Diggins, Luke Slind, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Human Cytomegalovirus UL78 is a Nuclear-Localized GPCR Necessary for Efficient Reactivation from Latent Infection in CD34 + Hematopoietic Progenitor CellsSamuel Medica, Nicole L Diggins, Michael Denton, et al.
Journal of Virology|May 16, 2014
Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoesPankaj Pal, Julie M Fox, David W Hawman, et al.
Vaccines|August 29, 2024
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural InfectionWhitney C Weber, Zachary J Streblow, Craig N Kreklywich, et al.
Pageof 5